Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;54(2):194–205. doi: 10.1038/s12276-022-00735-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a–c Heatmap representation of transcriptome array data for the expression levels of m6A-associated regulators in AML from the TCGA-AML, GSE14468, and OHSU-AML datasets. d Both IGF2BP3 and HNRNPA2B1 are significantly differentially regulated m6A functional effectors in different datasets. e A forest plot showing the HR and 95% CI for the association between IGF2BP3 and HNRNPA2B1 candidate genes and overall survival times in patients with AML calculated by univariate Cox regression analysis. f Real-time PCR was used to determine the expression of IGF2BP3 in bone marrow specimens from patients with AML. g The aberrantly high expression of IGF2BP3 in AML patients was significantly correlated with more unfavorable clinical characteristics on measures such as cytogenetic risk stratification. h Expression of IGF2BP3 mRNA with increasing age. i, j IGF2BP3 expression was lowest in patients with the AML-M3 subtype (French-American-British classification) and higher in patients with RUNX1 mutation. k–n Kaplan–Meier survival analysis showed that AML patients with high IGF2BP3 expression exhibited worse overall survival, based on analysis of TCGA, TARGET, GSE37642, and OHSU-AML datasets. o Pancancer analysis of 9652 tumor patients in the TCGA cohort showed that high expression of IGF2BP3 was strongly associated with poor prognosis. *P < 0.05; **P < 0.01; ***P < 0.001.